These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2134217)

  • 1. Glucose, insulin and C-peptide secretion in obese and non obese women with polycystic ovarian disease.
    Mahabeer S; Naidoo C; Joubert SM
    Diabetes Res; 1990 Jun; 14(2):79-82. PubMed ID: 2134217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin and C-peptide secretion in non-obese patients with polycystic ovarian disease.
    Mahabeer S; Jialal I; Norman RJ; Naidoo C; Reddi K; Joubert SM
    Horm Metab Res; 1989 Sep; 21(9):502-6. PubMed ID: 2684835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin hypersecretion together with high luteinizing hormone concentration augments androgen secretion in oral glucose tolerance test in women with polycystic ovarian disease.
    Anttila L; Koskinen P; Jaatinen TA; Erkkola R; Irjala K; Ruutiainen K
    Hum Reprod; 1993 Aug; 8(8):1179-83. PubMed ID: 8408513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin, C-peptide, androgens, and beta-endorphin response to oral glucose in patients with polycystic ovary syndrome.
    Tropeano G; Lucisano A; Liberale I; Barini A; Vuolo IP; Martino G; Menini E; Dell'Acqua S
    J Clin Endocrinol Metab; 1994 Feb; 78(2):305-9. PubMed ID: 8106616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for insulin resistance in nonobese patients with polycystic ovarian disease.
    Jialal I; Naiker P; Reddi K; Moodley J; Joubert SM
    J Clin Endocrinol Metab; 1987 May; 64(5):1066-9. PubMed ID: 2951393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
    Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
    Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycystic ovary disease. A risk factor for gestational diabetes?
    Lanzone A; Caruso A; Di Simone N; De Carolis S; Fulghesu AM; Mancuso S
    J Reprod Med; 1995 Apr; 40(4):312-6. PubMed ID: 7623362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overnight secretion pattern of growth hormone, sex hormone binding globulin, insulin-like growth factor-1 and its binding protein in obese and non-obese women with polycystic ovarian disease.
    Insler V; Barash A; Shoham Z; Koistinen R; Seppala M; Hen M; Lunenfeld B; Zadik Z
    Isr J Med Sci; 1994 Jan; 30(1):42-7. PubMed ID: 7511134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of opioid blockade on insulin metabolism in polycystic ovarian disease.
    Fulghesu AM; Ciampelli M; Fortini A; Cucinelli F; Guido M; Caruso A; Lanzone A; Mancuso S
    Hum Reprod; 1995 Sep; 10(9):2253-7. PubMed ID: 8530646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin resistance and secretion in polycystic ovarian disease.
    Bruno B; Poccia G; Fabbrini A
    J Endocrinol Invest; 1985 Oct; 8(5):443-8. PubMed ID: 2934464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease.
    Burghen GA; Givens JR; Kitabchi AE
    J Clin Endocrinol Metab; 1980 Jan; 50(1):113-6. PubMed ID: 7350174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the correlation between insulin like factor 3, polycystic ovary syndrome, and ovarian maldescent.
    Seyam E; Hefzy E
    Gynecol Endocrinol; 2018 Jun; 34(6):481-488. PubMed ID: 29254383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin secretion in polycystic ovarian disease: effect of ovarian suppression by GnRH agonist.
    Lanzone A; Fulghesu AM; Andreani CL; Apa R; Fortini A; Caruso A; Mancuso S
    Hum Reprod; 1990 Feb; 5(2):143-9. PubMed ID: 2108986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance.
    Sepilian V; Nagamani M
    J Soc Gynecol Investig; 2005 Feb; 12(2):129-34. PubMed ID: 15695109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin secretion in obese and non-obese women with polycystic ovary syndrome and its relationship with hyperandrogenism.
    dos Reis RM; Foss MC; de Moura MD; Ferriani RA; Silva de Sá MF
    Gynecol Endocrinol; 1995 Mar; 9(1):45-50. PubMed ID: 7793299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No acute effect of physiological insulin increase on dehydroepiandrosterone sulfate in women with obesity and/or polycystic ovarian disease.
    Buyalos RP; Bradley EL; Judd HL; Zacur HA; Azziz R
    Fertil Steril; 1991 Dec; 56(6):1179-82. PubMed ID: 1835937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Characteristics of glucose metabolism in non-obese and obese women with polycystic ovarian syndrome].
    Shi YH; Zhao DN; Zhao JL; You L; Liu H; Sun M; Chen ZJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Aug; 45(8):575-7. PubMed ID: 21029611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polycystic ovary syndrome: obesity, insulin resistance, hyperandrogenism.
    Lo Dico G; Alongi G; Savatteri L; Rini GB; Mascellino MR; Di Fede G; Rizzo G
    Acta Eur Fertil; 1989; 20(5):309-13. PubMed ID: 2700062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperinsulinemia in polycystic ovary disease.
    Arthur LS; Selvakumar R; Seshadri MS; Seshadri L
    J Reprod Med; 1999 Sep; 44(9):783-7. PubMed ID: 10509302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty-four-hour serum growth hormone, insulin, C-peptide and blood glucose profiles and serum insulin-like growth factor-I concentrations in women with polycystic ovaries.
    Prelević GM; Wurzburger MI; Balint-Perić L; Ginsburg J
    Horm Res; 1992; 37(4-5):125-31. PubMed ID: 1490653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.